Kyowa Kirin Co. Ltd
Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a… Read more
Market Cap & Net Worth: Kyowa Kirin Co. Ltd (KYKOF)
Kyowa Kirin Co. Ltd (PINK:KYKOF) has a market capitalization of $7.72 Billion ($7.72 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #3601 globally and #2346 in its home market, demonstrating a 8.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kyowa Kirin Co. Ltd's stock price $14.75 by its total outstanding shares 523488180 (523.49 Million).
Kyowa Kirin Co. Ltd Market Cap History: 2015 to 2025
Kyowa Kirin Co. Ltd's market capitalization history from 2015 to 2025. Data shows growth from $6.80 Billion to $7.72 Billion (0.66% CAGR).
Kyowa Kirin Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kyowa Kirin Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Kyowa Kirin Co. Ltd's market cap is 0.02 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.12x
Kyowa Kirin Co. Ltd's market cap is 0.12 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.11 Billion | $343.02 Billion | $18.67 Billion | 0.02x | 0.33x |
| 2017 | $8.72 Billion | $353.38 Billion | $42.90 Billion | 0.02x | 0.20x |
| 2018 | $8.97 Billion | $346.53 Billion | $54.41 Billion | 0.03x | 0.16x |
| 2019 | $10.00 Billion | $305.82 Billion | $67.08 Billion | 0.03x | 0.15x |
| 2020 | $12.49 Billion | $318.35 Billion | $47.03 Billion | 0.04x | 0.27x |
| 2021 | $13.68 Billion | $352.25 Billion | $52.35 Billion | 0.04x | 0.26x |
| 2022 | $10.85 Billion | $398.37 Billion | $53.57 Billion | 0.03x | 0.20x |
| 2023 | $8.47 Billion | $442.23 Billion | $81.19 Billion | 0.02x | 0.10x |
| 2024 | $8.40 Billion | $495.56 Billion | $59.87 Billion | 0.02x | 0.14x |
| 2025 | $7.72 Billion | $497.26 Billion | $67.10 Billion | 0.02x | 0.12x |
Competitor Companies of KYKOF by Market Capitalization
Companies near Kyowa Kirin Co. Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Kyowa Kirin Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kyowa Kirin Co. Ltd Historical Marketcap From 2015 to 2025
Between 2015 and today, Kyowa Kirin Co. Ltd's market cap moved from $6.80 Billion to $ 7.72 Billion, with a yearly change of 0.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $7.72 Billion | -8.10% |
| 2024 | $8.40 Billion | -0.84% |
| 2023 | $8.47 Billion | -21.88% |
| 2022 | $10.85 Billion | -20.71% |
| 2021 | $13.68 Billion | +9.51% |
| 2020 | $12.49 Billion | +24.94% |
| 2019 | $10.00 Billion | +11.45% |
| 2018 | $8.97 Billion | +2.84% |
| 2017 | $8.72 Billion | +42.83% |
| 2016 | $6.11 Billion | -10.16% |
| 2015 | $6.80 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Kyowa Kirin Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.72 Billion USD |
| MoneyControl | $7.72 Billion USD |
| MarketWatch | $7.72 Billion USD |
| marketcap.company | $7.72 Billion USD |
| Reuters | $7.72 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.